User profiles for Nathan Constantine-Cooke
 | Nathan Constantine-CookePostdoctoral Research Associate, University of Edinburgh Verified email at ed.ac.uk Cited by 68 |
Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis
LA Lucaciu, N Constantine-Cooke… - Therapeutic …, 2021 - journals.sagepub.com
Background and aims: Tofacitinib is a Janus kinase inhibitor (JAKi) recently approved for the
treatment of moderate to severe ulcerative colitis (UC) based on robust efficacy and safety …
treatment of moderate to severe ulcerative colitis (UC) based on robust efficacy and safety …
Effectiveness and safety of adalimumab biosimilar SB5 in inflammatory bowel disease: outcomes in originator to SB5 switch, double biosimilar switch and bio-naïve …
…, SI Siakavellas, N Constantine-Cooke… - Journal of Crohn's …, 2021 - academic.oup.com
Background and Aims Multiple adalimumab [ADA] biosimilars are now approved for use in
inflammatory bowel disease [IBD]; however, effectiveness and safety data remain scarce. We …
inflammatory bowel disease [IBD]; however, effectiveness and safety data remain scarce. We …
[HTML][HTML] Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn's Disease
N Constantine-Cooke, K Monterrubio-Gómez… - Clinical …, 2023 - Elsevier
Background and Aims The progressive nature of Crohn's disease is highly variable and
hard to predict. In addition, symptoms correlate poorly with mucosal inflammation. There is …
hard to predict. In addition, symptoms correlate poorly with mucosal inflammation. There is …
Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
B Gros, N Plevris, N Constantine‐Cooke… - United European …, 2023 - Wiley Online Library
Background Switching from originator infliximab (IFX) to biosimilar IFX is effective and safe.
However, data on multiple switching are scarce. The Edinburgh inflammatory bowel disease (…
However, data on multiple switching are scarce. The Edinburgh inflammatory bowel disease (…
Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis
…, L Lucaciu, N Constantine‐Cooke… - Alimentary …, 2022 - Wiley Online Library
Objective It is unclear how the compounding prevalence of inflammatory bowel disease (IBD)
has translated into the causes and rates of hospitalisation, particularly in an era of …
has translated into the causes and rates of hospitalisation, particularly in an era of …
A review on competing risks methods for survival analysis
K Monterrubio-Gómez, N Constantine-Cooke… - arXiv preprint arXiv …, 2022 - arxiv.org
When modelling competing risks survival data, several techniques have been proposed in
both the statistical and machine learning literature. State-of-the-art methods have extended …
both the statistical and machine learning literature. State-of-the-art methods have extended …
A review on statistical and machine learning competing risks methods
…, N Constantine‐Cooke… - Biometrical …, 2024 - Wiley Online Library
When modeling competing risks (CR) survival data, several techniques have been proposed
in both the statistical and machine learning literature. State‐of‐the‐art methods have …
in both the statistical and machine learning literature. State‐of‐the‐art methods have …
Effectiveness and safety of Adalimumab biosimilar SB5 in IBD: outcomes in originator to SB5 switch, double biosimilar switch and bio-naieve SB5 observational …
…, SI Siakavellas, N Constantine-Cooke… - Journal of Crohn's …, 2021 - research.ed.ac.uk
BACKGROUND AND AIMS: Multiple adalimumab (ADA) biosimilars are now approved for
use in IBD; however, effectiveness and safety data remain scarce. We aimed to investigate …
use in IBD; however, effectiveness and safety data remain scarce. We aimed to investigate …
[HTML][HTML] Rates, predictive factors and effectiveness of ustekinumab intensification to 4-or 6-weekly intervals in Crohn's disease
…, M Lyons, SI Siakavellas, N Constantine-Cooke… - Digestive and Liver …, 2023 - Elsevier
Background The UNITI trial reports efficacy of ustekinumab (UST) dose intensification in
Crohn's disease (CD) from 12- to 8-weekly, but not 4-weekly. We aimed 1) to assess the …
Crohn's disease (CD) from 12- to 8-weekly, but not 4-weekly. We aimed 1) to assess the …
[HTML][HTML] Real-world effectiveness of upadacitinib in Crohn's disease: a UK multicentre retrospective cohort study
…, N Plevris, B Gros, N Constantine-Cooke… - Frontline …, 2024 - fg.bmj.com
Background Upadacitinib is a Janus kinase inhibitor, which has recently been approved for
treating Crohn’s disease. There are limited real-world studies on the outcomes of …
treating Crohn’s disease. There are limited real-world studies on the outcomes of …